Evidence map›Paper›PMID 35643877›Full record

ArticleMolecular and cellular biochemistry2022

Dose-dependent effects of perfluorocarbon-based blood substitute on cardiac function in myocardial ischemia-reperfusion injury.

Vladimir Jakovljevic, Sergey Vorobyev, Sergey Bolevich, Elena Morozova, Stefani Bolevich, Alexander Saltykov, Peter Litvickiy, Vladimir Fisenko, Alexander Tsymbal, Alexandra Orlova and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 2 countries.

Vladimir JakovljevicFaculty of Medical Sciences, Department of Physiology, University of Kragujevac, Svetozara Markovića 69, 34000, Kragujevac, Serbia. drvladakgbg@yahoo.com.ORCID http://orcid.org/0000-0002-0071-8376
Sergey VorobyevDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Sergey BolevichDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Elena MorozovaDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Stefani BolevichDepartment of Pathophysiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Alexander SaltykovDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Peter LitvickiyDepartment of Pathophysiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Vladimir FisenkoDepartment of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Alexander TsymbalDepartment of Pathophysiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Alexandra OrlovaDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Tatiana SinelnikovaDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Maria KruglovaDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Ekaterina SilinaDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Anastasia MikhalevaDepartment of Human Pathology, First Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2 119991, Moscow, Russian Federation.
Isidora MilosavljevicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Jasmina SretenovicFaculty of Medical Sciences, Department of Physiology, University of Kragujevac, Svetozara Markovića 69, 34000, Kragujevac, Serbia.
Vladislava StojicDepartment of Statistics and Informatics, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Jovana JeremicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Tamara Nikolic TurnicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Sechenov University · RUUniversity of Kragujevac · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main goal of this study was to investigate the cardioprotective properties in terms of effects on cardiodynamics of perfluorocarbon emulsion (PFE) in ex vivo-induced ischemia-reperfusion injury of an isolated rat heart. The first part of the study aimed to determine the dose of 10% perfluoroemulsion (PFE) that would show the best cardioprotective effect in rats on ex vivo-induced ischemia-reperfusion injury of an isolated rat heart. Depending on whether the animals received saline or PFE, the animals were divided into a control or experimental group. They were also grouped depending on the applied dose (8, 12, 16 ml/kg body weight) of saline or PFE. We observed the huge changes in almost all parameters in the PFE groups in comparison with IR group without any pre-treatment. Calculated in percent, dp/dt max was the most changed parameter in group treated with 8 mg/kg, while the dp/dt min, SLVP, DLVP, HR, and CF were the most changed in group treated with 16 mg/kg 10 h before ischemia. The effects of 10% PFE are more pronounced if there is a longer period of time from application to ischemia, i.e., immediate application of PFE before ischemia (1 h) gave the weakest effects on the change of cardiodynamics of isolated rat heart. Therefore, the future of PFE use is in new indications and application methods, and PFE can also be referred to as antihypoxic and antiischemic blood substitute with mild membranotropic effects.

Indexed as

Blood SubstitutesFluorocarbonsMyocardial Reperfusion InjuryAnimalsCardiovascular Physiological PhenomenaRatsBlood SubstitutesFluorocarbonsCardiodynamic parametersEx vivo-induced ischemia–reperfusion injuryIsolated rat heartPerfluoroemulsion

Identifiers

PMID35643877
OpenAlexW4282942326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.